United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised 9,500 stock options at $146.03 per share and acquired 9,500 shares of common stock on March 24, 2026. She then sold 9,500 common shares in multiple open‑market trades at prices between approximately $516.84 and $536.02, leaving 40,513 shares held directly.
The filing also lists additional indirect holdings, including shares held by her spouse and in various family trusts. A footnote states these transactions were made under a pre‑arranged 10b5‑1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 9,500 shares ($5,028,919)
Net Sell
24 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.03M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 9,500 | $0.00 | -- |
| Exercise | Common Stock | 9,500 | $146.03 | $1.39M |
| Sale | Common Stock | 40 | $516.8363 | $21K |
| Sale | Common Stock | 280 | $519.099 | $145K |
| Sale | Common Stock | 120 | $520.7545 | $62K |
| Sale | Common Stock | 400 | $521.85 | $209K |
| Sale | Common Stock | 527 | $522.8879 | $276K |
| Sale | Common Stock | 737 | $523.9252 | $386K |
| Sale | Common Stock | 256 | $524.6244 | $134K |
| Sale | Common Stock | 480 | $525.9321 | $252K |
| Sale | Common Stock | 680 | $526.9436 | $358K |
| Sale | Common Stock | 400 | $528.02 | $211K |
| Sale | Common Stock | 280 | $529.4841 | $148K |
| Sale | Common Stock | 480 | $530.7341 | $255K |
| Sale | Common Stock | 1,605 | $532.2392 | $854K |
| Sale | Common Stock | 1,890 | $533.2082 | $1.01M |
| Sale | Common Stock | 709 | $534.3123 | $379K |
| Sale | Common Stock | 536 | $535.3867 | $287K |
| Sale | Common Stock | 80 | $536.02 | $43K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 78,500 shares (Direct);
Common Stock — 50,013 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (1)
- This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. This transaction was executed in multiple trades at prices ranging from $526.50 to $527.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $527.59 to $528.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $529.26 to $530.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $530.26 to $531.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $531.74 to $532.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $532.76 to $533.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $533.92 to $534.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $535.10 to $535.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. This transaction was executed in multiple trades at prices ranging from $516.71 to $516.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. This transaction was executed in multiple trades at prices ranging from $518.435 to $519.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $520.11 to $521.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $521.30 to $522.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $522.32 to $523.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $523.32 to $524.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $524.43 to $525.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $525.43 to $526.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
FAQ
What insider transactions did UTHR CEO Martine Rothblatt report on March 24, 2026?
Martine Rothblatt exercised 9,500 stock options at $146.03 per share and acquired 9,500 common shares, then sold 9,500 common shares in multiple open‑market trades at prices around $517–$536, leaving 40,513 shares held directly.
Was the UTHR CEO’s March 24, 2026 stock sale pre-planned?
Yes. The exercise of stock options and sale of the resulting common shares occurred under a pre‑arranged 10b5‑1 trading plan adopted on November 7, 2025, indicating these transactions were scheduled in advance rather than timed discretionarily.
What stock option position did the UTHR CEO exercise in this Form 4 filing?
The CEO exercised 9,500 stock options with an exercise price of $146.03 per share, converting them into 9,500 common shares. These options are part of a larger pool of 1,734,410 stock options that expire on March 17, 2027 under the referenced 10b5‑1 plan.
What does the 10b5-1 trading plan mentioned in the UTHR Form 4 allow?
The 10b5‑1 plan allows the CEO to exercise up to 1,734,410 stock options, all expiring March 17, 2027, with the plan running until the earlier of completing those exercises or December 31, 2026. The March 24, 2026 trades occurred pursuant to this plan.